Rock Springs Capital
Baltimore, Maryland, United StatesFounded 2013
Rock Springs Capital is a hedge fund primarily focused on investing in the healthcare and life sciences sectors. The firm employs a fundamental, research-driven, long/short equity strategy, specializing in growth equity and late-stage venture capital investments in companies with promising growth prospects and strong management teams.
73% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (50% of deals). Average disclosed round size is $145.1M (across 22 rounds with reported amounts).
Portfolio
22
Fund Size
$5.8B
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
22 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
 Leap Therapeutics | Series B | $40M | Apr 2024 |
 Overjet | Series C | $53.2M | Mar 2024 |
 Avalyn Pharma Inc. | Series C | $175M | Sep 2023 |
 Hemab Therapeutics | Series B | $135M | Feb 2023 |
 Mineralys Therapeutics, Inc. | Series B | $118M | Jun 2022 |
 Disc Medicine | Series B | $90M | Sep 2021 |
| MMiRXES Pte | Series C | $77M | Jul 2021 |
 Kindbody | Series C | $62M | Jun 2021 |
 Caris Life Sciences | Growth | $830M | May 2021 |
 DELFI Diagnostics, Inc. | Series A | $100M | Jan 2021 |
| Kindbody | Series B | $32M | Jul 2020 |
 Bolt Biotherapeutics | Series C | $93.5M | Jul 2020 |
 Athira Pharma, Inc. | Series B | $85M | Jun 2020 |
| EEverest Medicines | Series C | $310M | Jun 2020 |
 Akero Therapeutics | Series B | $70M | Dec 2018 |
 Aprea Therapeutics | Series C | $50M | Nov 2018 |
 Innovent Biologics, Inc. | Series E | $150M | Apr 2018 |
 Spark Therapeutics | Series B | $72.8M | May 2014 |
 Treeline Biosciences | Series A | $261M | — |
 Genesis Therapeutics | Series B | $200M | — |
 SwiftConnect | Series B | $37M | — |
Top Co-Investors
Janus Henderson Investors4 shared
Cormorant Asset Management4 shared
RA Capital Management4 shared
Samsara BioCapital4 shared
OrbiMed4 shared
T. Rowe Price Associates, Inc.4 shared
Novo Holdings3 shared
Access Biotechnology3 shared
Perceptive Advisors3 shared
Surveyor Capital3 shared
Sofinnova Partners3 shared
Redmile Group2 shared
Atlas Venture2 shared
Versant Ventures2 shared
RTW Investments2 shared
SR One2 shared
Sectoral Asset Management2 shared
Hillhouse Capital2 shared
HealthCap2 shared
Alexandria Venture Investments2 shared
Last updated: 16 April 2026